Category Archives: Cell Therapy

NEW YORK, NY and PETAH TIKVA, ISRAEL--(Marketwired - Jul 29, 2013) - BrainStorm Cell Therapeutics (OTCQB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that the European Commission has granted Orphan Drug Designation for NurOwn, the Company's stem cell therapy consisting of autologous bone marrow-derived mesenchymal stromal cells secreting neurotrophic factors, for the treatment of Amyotrophic Lateral Sclerosis (ALS), also known as Lou Gehrig's Disease.NurOwn received Orphan Drug Designation from the Food and Drug Administration (FDA) in 2011.

Orphan drugs benefit from 10 years market exclusivity in the European Union (EU) after marketing approval. Additional benefits for sponsor companies include reduced fees for various centralized activities including applications for marketing authorization, inspections and protocol assistance, as well as possible eligibility for EU grants and other R&D-supporting initiatives.

BrainStorm is currently conducting a Phase IIa dose-escalating trial with 12 ALS patients at the Hadassah Medical Center in Jerusalem, Israel. The company anticipates launching a Phase II multi-center trial at three leading institutions in the United States towards the end of 2013, pending FDA approval.

About BrainStorm Cell Therapeutics, Inc.BrainStorm Cell Therapeutics Inc. is a biotechnology company engaged in the development of first-of-its-kind adult stem cell therapies derived from autologous bone marrow cells for the treatment of neurodegenerative diseases. The Company holds the rights to develop and commercialize its NurOwn technology through an exclusive, worldwide licensing agreement with Ramot, the technology transfer company of Tel Aviv University. For more information, visit the company's website at http://www.brainstorm-cell.com.

Safe Harbor Statement - Statements in this announcement other than historical data and information constitute "forward-looking statements" and involve risks and uncertainties that could cause BrainStorm Cell Therapeutics Inc.'s actual results to differ materially from those stated or implied by such forward-looking statements. Terms and phrases such as "may", "should", "would", "could", "will", "expect", "likely", "believe", "plan", "estimate", "predict", "potential", and similar terms and phrases are intended to identify these forward-looking statements.The potential risks and uncertainties include, without limitation, risks associated with BrainStorm's limited operating history, history of losses; minimal working capital, dependence on its license to Ramot's technology; ability to adequately protect the technology; dependence on key executives and on its scientific consultants; ability to obtain required regulatory approvals; and other factors detailed in BrainStorm's annual report on Form 10-K and quarterly reports on Form 10-Q available at http://www.sec.gov.These factors should be considered carefully, and readers should not place undue reliance on BrainStorm's forward-looking statements.The forward-looking statements contained in this press release are based on the beliefs, expectations and opinions of management as of the date of this press release. We do not assume any obligation to update forward-looking statements to reflect actual results or assumptions if circumstances or management's beliefs, expectations or opinions should change, unless otherwise required by law. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements.

Continue reading here:
BrainStorm's NurOwn Cell Therapy Receives Orphan Drug Designation in the European Union for ALS

FAQ4 A Scientific Basis for Stem Cell Therapy
http://youtu.be/uf_toA9Nzuo With all the hype online and in the media today, it is easy to believe that Stem Cell therapy is ALSO #39;hype #39;, but it actually eme...

By: Kerry Dean

View original post here:
FAQ4 A Scientific Basis for Stem Cell Therapy - Video

ALAMEDA, Calif.--(BUSINESS WIRE)--LifeMap Sciences, Inc. announced today the release of LifeMap Discovery version 1.2 (discovery.lifemapsc.com). LifeMap Discovery is a state-of-the-art roadmap of embryonic development and stem cell biology. The product integrates embryonic development and stem cell biology, molecular, cellular, anatomical, and disease-related information, and provides data-mining capabilities and bioinformatics applications. As such, it is a unique and powerful tool for research and discovery in multiple disciplines, including stem cell biology, developmental biology and disease mechanisms and etiology.

LifeMap Discovery version 1.2 provides enhanced features related to stem cell therapeutic development

LifeMap Discovery is a key component in LifeMaps integrated database suite, a discovery platform for biomedical and stem cell research, which also includes GeneCards, the leading human gene database, and MalaCards, the human disease database.

LifeMap Discovery version 1.2 new features and information include the following:

LifeMap Discovery version 1.2 provides enhanced features related to stem cell therapeutic development, said Ronit Shtrichman, Ph.D., MBA, Vice President of Biology at LifeMap Sciences. This version includes substantially upgraded information about stem cells with potential therapeutic applications and stem cell differentiation protocols. It also enables researchers to identify genes specifically expressed during embryonic development and stem cells differentiation, providing the means to generate desired cell types for therapeutic applications.

The extensive coverage of the stem cell therapy pipeline and high throughput gene expression data are significant steps forward in developing our premium model, and are of significant interest to companies developing cell-based therapies. Coupled with the commercial offering of recombinant proteins and PureStem progenitors, it is an important milestone for commercialization of the LifeMap Discovery platform, stated Yaron Guan-Golan, Head of Marketing at LifeMap Sciences.

About LifeMap Sciences, Inc.

LifeMap Sciences (www.lifemapsc.com) core technology and business is based on the LifeMap Integrated Biomedical Knowledgebase, the discovery platform for biomedical and stem cell research. This web-based platform includes GeneCards, the leading human gene compendium; LifeMap Discovery, the embryonic development, stem cell research and regenerative medicine compendium; and MalaCards, the human disease compendium. According to Google Analytics, the sites have generated more than 2,000,000 unique visitors with more than 13,000,000 page views, from more than 3,000 universities, institutions and biomedical companies in the past 12 months.

Via LifeMap BioReagents, LifeMap offers leading edge reagents to researchers in academia, research hospitals, and biotech and pharma companies. LifeMap is BioTimes principal marketing subsidiary for research products, including PureStem human progenitor cells, PureStem packages, clinical and research grade human embryonic stem cell (hES) lines, culture media, and cell differentiation kits. The eCommerce portal also offers select recombinant proteins, including growth factors, signaling molecules, differentiation factors, cytokines and chemokines that complement BioTimeresearch product lines.

In therapeutic discovery collaboration with BioTime, LifeMaps scientists utilize the Integrated Biomedical Knowledgebase to aid in the development of BioTimes proprietary library of more than 200 PureStem human progenitor cell types into products for the treatment of human diseases, especially degenerative diseases that might be treatable with cell replacement therapies. A bioinformatics platform developed by LifeMap is used to select the PureStem cells that are most likely to be useful in developing cell-based regenerative medicine therapies for a wide range of diseases.

Read more:
LifeMap Sciences Announces Release of LifeMap Discovery™ Version 1.2 With Extensive Stem Cell Therapy Data

TULSA, Oklahoma -

A controversial therapy that's not available for humans is being used on their pets. Stem cells are helping dogs and cats heal faster and get rid of pain as the animals get older.

Mandy Clinton loves her dog and she'd do just about anything for her.

"I've had her for 14 years. She's my homegirl," Clinton said about Libbi.

But Libbi has come up with a hitch in her giddy up. She tripped while walking up the stairs and tore her ACL.

Clinton was looking into surgery when she learned about stem cell therapy and its ability to help dogs heal faster and reduce pain.

"I had no idea. I had no idea. It blew my mind, but I've had Libbi for 14 years, and so I was ready to do it if it was possible," she said.

Dr. Joe Landers at Heritage Veterinary Hospital will be performing Libbi's surgery on Wednesday.

They'll harvest stem cells from Libbi's stomach, process and stimulate them, then implant the stem cells on her leg joint.

"If you've ever cut your skin, deeply with a knife or something, you've had stem cell repair," said Dr. Joe Landers, DVM.

More here:
Oklahoma Veterinarian Offering Stem Cell Therapy For Aging Pets

Arthritis Treatment Center What is Stem Cell Therapy
http://www.arthritistreatmentcenter.com/what_stem_cell.html - This facts will truly surprise you and your family.

By: Joseph Richardson

More here:
Arthritis Treatment Center What is Stem Cell Therapy - Video

(PRWEB) July 22, 2013

The Institute of Regenerative and Molecular Orthopaedics (IRMO), world-renowned stem cell therapy experts, applauds the use of stem cell therapy for treatment of spinal injuries. In recent times, stem cell therapy has been increasingly sought after to support treatments of various injuries, especially in the sports world. Its use in repairing spinal injuries comes as good news to the thousands of Americans currently living with spinal cord injuries who are seeking the latest in breakthrough medical solutions.

Stem cell therapy is of the most exciting and promising treatments in modern medicine. Inroads are made every day, as the many applications of stem cell treatments become better understood by medical professionals around the world. Experts, like Dr. Joseph Purita of the Institute of Regenerative and Molecular Orthopaedics, have been utilizing stem cell treatments for many years to treat sports injuries.

Recent scientific and technological advancements have made stem cell extraction relatively inexpensive and accessible. Today, medical professionals have unprecedented access to these remarkable cells and are increasingly applying them in new ways to better aid in the bodys repair process. This includes advances in platelet rich plasma therapy (PRP), a process that takes a concentration of a persons own plasma and injects it into areas in need of new growth and tissue repair.

The use of stem cell therapy in the treatment of spinal cord injuries presents probably the biggest challenge yet for proponents of the treatment. Researchers are increasingly using stem cells to hopefully better understand its capabilities. The hope for spinal cord injuries is that one day stem cells can be used to generate new passageways for nerve signals to connect to muscles. The more stem cells are used for treatment in spinal cord injuries, the closer the medical field will be to fulfilling this promise.

Headed by the world-renowned stem cell treatment pioneer, Dr. Purita, the Institute of Regenerative and Molecular Orthopaedics is continually advancing the world of stem cell therapy treatments. They are one of the few orthopedic practices in existence that utilizes stem cell therapy, and PRP therapy, with orthopedic surgery to maximize a patients recovery outcome. As more stem cell treatments are being used to treat spinal injuries, Dr. Purita and his group look forward to seeing what great strides are made in battling the crippling condition in the near future.

About Stem Cell Orthopedic: The Institute of Regenerative and Molecular Orthopaedics (IRMO) is a world-class orthopedic practice and stem cell facility staffed with seasoned board certified orthopedic surgeons. They differ from most orthopedic practices because they offer stem cells and platelet rich plasma (PRP) therapy in conjunction with surgery or as alternative to surgical procedures. They utilize state-of-the-art technology and the latest in stem cell research to best treat their patients. IRMO uses hematopoietic stem cells (HSC), which are found circulating in blood, fat, and bone marrow, to help repair the body. They are headed by Medical Director, Dr. Joseph Purita, a world-renowned pioneer in laser orthopedic surgery and graduate of the esteemed Georgetown University Medical School. For more information, visit http://www.stemcellorthopedic.com/ or follow them on Facebook, Twitter, or YouTube.

Read more here:
Stem Cell Orthopedic Applauds Use of Stem Cell Therapy for Spinal Injuries

LAST week, we discussed the potential of medical tourism in the country which will also provide opportunities for destinations like Baguio once tapped, and subject to competitive and international standards and government/ regulatory requirements.

So much has been written and reported about Stem Cell Therapy including its extraordinary promises that research holds for the treatment of a wide range of diseases and conditions.

This week, lets delve deeper.

What is Stem Cell Therapy?

Cell Therapy has been interchangeably called many names such as cellular therapy, fresh cell therapy, live cell therapy, glandular therapy, or xenograph or xenotransplant therapy.

The International Society for Stem Cell Research (ISSCR) describes stem cell therapy as a treatment that uses stem cells, or cells that come from stem cells, to replace or to repair a patients cells or tissues that are damaged. The stem cells might be put into the blood, or transplanted into the damaged tissue directly, or even recruited from the patients own tissues for self-repair.

Stem Cells have been differentiated based on where in the body or what stage in development they come from. ISCCR has enumerated them as follows (source:www.isscr.org):

1. Adult Stem Cells or Tissue-specific Stem Cells. Many adult tissues contain stem cells that can replace cells that die or restore tissue after injury. Skin, muscle, intestine and bone marrow, for example, each contain their own stem cells. In the bone marrow, billions of new blood cells are made every day from blood-forming stem cells. Adult stem cells are tissue-specific, meaning they are found in a given tissue in our bodies and generate the mature cell types within that particular tissue or organ. It is not clear whether all organs, such as the heart, contain stem cells. The term adult stem cells is often used very broadly and may include fetal and cord blood stem cells.

Another type of adult stem cell is the mesenchymal stem cell. These are found in a number of tissues, including bone marrow, and may be able to produce bone, cartilage and fat. It is also possible that these or similar cells may aid in the regeneration of tissues. Extensive animal studies are currently ongoing to determine if these cells may be used for treatment of diseases such as arthritis and non-healing bone fractures. It is also possible that these or similar cells modulate the immune system in response to injury.

2. Fetal Stem Cells. Fetal stem cells are taken from the fetus. The developing baby is referred to as a fetus from approximately 10 weeks of gestation. Most tissues in a fetus contain stem cells that drive the rapid growth and development of the organs. Like adult stem cells, fetal stem cells are generally tissue-specific, and generate the mature cell types within the particular tissue or organ in which they are found.

View original post here:
De Leon: Medical Tourism and the Future of Stem Cell Therapy (Part 2)

Stem Cell Therapy Used as Dog Arthritis Treatment
We have dedicated our careers to helping dogs live to the fullest extent possible. For more information please visit one of our articles below: Dog Arthritis...

By: Duncan Bulow

See the article here:
Stem Cell Therapy Used as Dog Arthritis Treatment - Video